NZ784931A - Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h-tetrazole-5-carboxamide - Google Patents

Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h-tetrazole-5-carboxamide

Info

Publication number
NZ784931A
NZ784931A NZ784931A NZ78493120A NZ784931A NZ 784931 A NZ784931 A NZ 784931A NZ 784931 A NZ784931 A NZ 784931A NZ 78493120 A NZ78493120 A NZ 78493120A NZ 784931 A NZ784931 A NZ 784931A
Authority
NZ
New Zealand
Prior art keywords
inden
oxadiazol
polymorphs
tetrazole
carboxamide
Prior art date
Application number
NZ784931A
Other languages
English (en)
Inventor
Norma TOM
Denise Andersen
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of NZ784931A publication Critical patent/NZ784931A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ784931A 2019-07-17 2020-07-16 Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h-tetrazole-5-carboxamide NZ784931A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962875355P 2019-07-17 2019-07-17
PCT/US2020/042390 WO2021011809A1 (en) 2019-07-17 2020-07-16 Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h-tetrazole-5-carboxamide

Publications (1)

Publication Number Publication Date
NZ784931A true NZ784931A (en) 2025-03-28

Family

ID=71995105

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ784931A NZ784931A (en) 2019-07-17 2020-07-16 Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h-tetrazole-5-carboxamide

Country Status (16)

Country Link
US (1) US12649732B2 (cg-RX-API-DMAC10.html)
EP (1) EP3999181B1 (cg-RX-API-DMAC10.html)
JP (1) JP2022542803A (cg-RX-API-DMAC10.html)
KR (1) KR20220082803A (cg-RX-API-DMAC10.html)
CN (1) CN114667283B (cg-RX-API-DMAC10.html)
AU (1) AU2020315433A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022000523A2 (cg-RX-API-DMAC10.html)
CA (1) CA3144974A1 (cg-RX-API-DMAC10.html)
CL (1) CL2022000089A1 (cg-RX-API-DMAC10.html)
ES (1) ES2982707T3 (cg-RX-API-DMAC10.html)
IL (1) IL289881A (cg-RX-API-DMAC10.html)
MX (1) MX2022000498A (cg-RX-API-DMAC10.html)
NZ (1) NZ784931A (cg-RX-API-DMAC10.html)
PH (1) PH12022550084A1 (cg-RX-API-DMAC10.html)
TW (1) TW202116764A (cg-RX-API-DMAC10.html)
WO (1) WO2021011809A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202006296YA (en) 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
MX2022000498A (es) 2019-07-17 2022-02-03 Cytokinetics Inc Polimorfos de (r)-n-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihi dro-1h-inden-1-il) -2-metil-2h- tetrazol-5-carboxamida.
CN120712262A (zh) * 2023-03-02 2025-09-26 苏州科睿思制药有限公司 Aficamten的共晶及其制备方法和用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399866B2 (en) * 2003-01-14 2008-07-15 Cytokinetics, Inc. Compounds, compositions, and methods
US7507735B2 (en) 2004-06-17 2009-03-24 Cytokinetics, Inc. Compounds, compositions and methods
US20060173183A1 (en) 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
AU2006284751A1 (en) 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
WO2007078815A2 (en) * 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US20090192168A1 (en) 2008-01-04 2009-07-30 Alex Muci Compounds, Compositions and Methods
MX2012000437A (es) 2009-07-08 2012-02-21 Chelsea Therapeutics Inc Polimorfos cristalinos estables de la sal dipotasica de acido (s)-2-{2,4-diamono-quizolin-6-il)-etil]-benzoilamino}-4-metilen-p entanodioico.
CA2772275A1 (en) 2009-09-18 2011-03-24 Sanofi (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
US8592426B2 (en) 2011-01-24 2013-11-26 Hoffmann—La Roche Inc. Aryl-benzocycloalkyl amide derivatives
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US9199945B2 (en) 2013-06-21 2015-12-01 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
EP3151671A4 (en) 2014-06-03 2018-03-07 Sulfagenix, Inc. Methods and compositions for treating nitric oxide deficiency disorders and related conditions
US9902702B2 (en) 2014-07-15 2018-02-27 Bristol-Myers Squibb Company Spirocycloheptanes as inhibitors of rock
DK3356345T3 (da) 2015-09-30 2024-02-12 Max Planck Gesellschaft Heteroaryl-derivater som sepiapterin-reduktase-inhibitorer
EP3156049A1 (en) 2015-10-15 2017-04-19 Alembic Pharmaceuticals Limited Pharmaceutical composition of prasugrel
JP2020526483A (ja) 2017-06-30 2020-08-31 アムジエン・インコーポレーテツド 心筋節活性化剤で心不全を治療する方法
BR112020004800A2 (pt) 2017-09-13 2020-09-24 Amgen Inc. compostos de bisamida ativantes do sarcômero e seus usos
SG11202006296YA (en) 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
MX2022000498A (es) 2019-07-17 2022-02-03 Cytokinetics Inc Polimorfos de (r)-n-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihi dro-1h-inden-1-il) -2-metil-2h- tetrazol-5-carboxamida.
LT3999180T (lt) 2019-07-17 2024-08-26 Cytokinetics, Inc. (r)-n-(5-(5-etil-1,2,4-oksadiazol-3-il)-2,3-dihidro-1h-inden-1-il)-1-metil-1h-pirazol-4-karboksamido polimorfai
WO2021011808A1 (en) 2019-07-17 2021-01-21 Cytokinetics, Inc. Cardiac sarcomere inhibitor oral formulations
EP4370116B1 (en) 2021-07-16 2025-01-15 Cytokinetics, Inc. Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
JP2024530111A (ja) 2021-08-03 2024-08-16 サイトキネティックス, インコーポレイテッド アフィカムテンを調製するための工程
US20240091203A1 (en) 2022-07-20 2024-03-21 Cytokinetics, Incorporated Methods for treating non-obstructive hypertrophic cardiomyopathy
JP2025525913A (ja) 2022-08-04 2025-08-07 サイトキネティックス, インコーポレイテッド 閉塞性肥大型心筋症を治療するための方法
WO2024134498A1 (en) 2022-12-22 2024-06-27 Assia Chemical Industries Ltd. Solid state forms of aficamten and process for preparation thereof
WO2024182469A1 (en) 2023-02-28 2024-09-06 MyoKardia, Inc. Myosin inhibitors for use in the treatment of hypertrophic cardiomyopathy
CN120712262A (zh) 2023-03-02 2025-09-26 苏州科睿思制药有限公司 Aficamten的共晶及其制备方法和用途
WO2025220034A1 (en) 2024-04-16 2025-10-23 Dr. Reddy’S Laboratories Limited "amorphous solid dispersion of aficamten and process for their preparation"

Also Published As

Publication number Publication date
BR112022000523A2 (pt) 2022-03-03
MX2022000498A (es) 2022-02-03
US12649732B2 (en) 2026-06-09
EP3999181B1 (en) 2024-05-29
CN114667283B (zh) 2023-12-26
WO2021011809A1 (en) 2021-01-21
EP3999181C0 (en) 2024-05-29
AU2020315433A1 (en) 2022-03-03
CN114667283A (zh) 2022-06-24
KR20220082803A (ko) 2022-06-17
US20220274969A1 (en) 2022-09-01
PH12022550084A1 (en) 2023-04-12
CA3144974A1 (en) 2021-01-21
TW202116764A (zh) 2021-05-01
IL289881A (en) 2022-03-01
JP2022542803A (ja) 2022-10-07
EP3999181A1 (en) 2022-05-25
ES2982707T3 (es) 2024-10-17
CL2022000089A1 (es) 2022-10-07

Similar Documents

Publication Publication Date Title
PH12022550123A1 (en) Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
PH12022550084A1 (en) Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h-tetrazole-5-carboxamide
PH12020551304A1 (en) Novel crystalline forms
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
PH12022550083A1 (en) Cardiac sarcomere inhibitor oral formulations
MX2021001433A (es) Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa.
MX2021015102A (es) Inhibidores del receptor del factor estimulante de colonias 1 (csf-1r).
IL199403A0 (en) 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl)phenyl]-1h-pyrazol-5-yl}carbamoyl)-amino]-3-fluorophenoxy}-n-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer
PH12020500105A1 (en) Bicyclic ketone compounds and methods of use thereof
CR20220004A (es) Nuevos compuestos heterocíclicos
PH12020550125A1 (en) Crystalline forms of 3-substituted 1,2,4-oxadiazole
CR20200610A (es) Nuevos derivados de isoxazolit éter como pan de gaba a alfa 5
MY201378A (en) Crystal forms of immunomodulators
BR112017012646A2 (pt) Formas sólidas compreendendo (1e, 4e)-2-amino- n,n-dipropil-8-(4-(pirrolidina-1-carbonil) fenil)-3h- benzo[b]azepina-4-carboxamida, composições das mesmas, e uso das mesmas
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
MX2023001805A (es) Formas solidas de 2-(5-(4-(2-morfolinoetoxi)fenil)piridin-2-il)-n- bencilacetamida.
IL294971B1 (en) Preparation of converted 3-aryl-5-trifluoromethyl-1,2,4-oxadiazoles
IL288577A (en) Formulations of (s)-3-amino-6-methoxy-n-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide
HK40074727A (en) Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h-tetrazole-5-carboxamide
MX381722B (es) Compuestos.
MY208901A (en) Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof
WO2020055359A3 (en) Oral dosage form of sorafenib tosylate
HK40064881A (en) Formulations of (s)-3-amino-6-methoxy-n-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide
HK40075684B (en) Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
PH12019502560A1 (en) The salts of a compound and the crystalline forms thereof